High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies

High frequencies of <i>KRAS</i> and <i>GNAS</i> mutations support the proposed role as driver mutations and as potential therapy targets. The primary tumor may serve as an alternative source of tumor material, increasing the likelihood of detecting targetable mutations. Combined with highly sensitive analytical methods, this approach facilitates selection of patients for novel targeted therapeutic strategies.